BCMA-Directed CAR T-Cell Therapy: Outlook

First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myelomaПодробнее

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multip...Подробнее

CAR T-cells directed against BCMA in MMПодробнее

Can a patient use a different CAR-T target after receiving BCMA directed therapy?Подробнее

Idecabtagene vicleucel, a BCMA-directed CAR T cell therapy, in RRMM: Updated KarMMa resultsПодробнее

BCMA-Targeted CAR T-Cell Therapy for MyelomaПодробнее

Phase 1 Study PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023Подробнее

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r mu...Подробнее

Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple MyelomaПодробнее

PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myelomaПодробнее

CAR T-cells in Multiple MyelomaПодробнее

What is CAR-T Cell Therapy?Подробнее

BCMA-Directed CAR-T Therapy for Patients With Relapsed/Refractory Multiple MyelomaПодробнее

Predictors of T Cell Expansion and Clinical Responses Following CART-BCMA for RRMMПодробнее

A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig HofmeisterПодробнее

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее

Natalie Callander, MD, Discusses BCMA CAR T Cell Therapy for Multiple MyelomaПодробнее

Integrating BCMA-directed bispecifics and CAR-T into the myeloma treatment landscapeПодробнее

CAR T-cells: targeting BCMAПодробнее

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple MyelomaПодробнее